Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
Public ClinicalTrials.gov record NCT05804370. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3 Multicenter Study of Gleolan® (Aminolevulinic Acid Hydrochloride) to Enhance Visualization of Tumor in Patients With Suspected Newly Diagnosed or Recurrent Epithelial Ovarian Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This Phase 3 study is designed to investigate the safety, diagnostic performance, and clinical usefulness of Gleolan for the real-time detection and visualization of epithelial ovarian cancer tumors during debulking surgery. The study is planned to run for about 18 months with individual study participation lasting about two (2) weeks.
Study identification
- NCT ID
- NCT05804370
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 170 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 29, 2024
- Primary completion
- Aug 31, 2028
- Completion
- Apr 30, 2029
- Last update posted
- Jul 13, 2026
2024 – 2029
United States locations
- U.S. sites
- 11
- U.S. states
- 9
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic Arizona | Phoenix | Arizona | 85054 | Recruiting |
| Mayo Clinic Florida | Jacksonville | Florida | 32224 | Recruiting |
| Luminis Health Anne Arundel Medical Center | Annapolis | Maryland | 21401 | Completed |
| University of Maryland | Baltimore | Maryland | 21201 | Recruiting |
| Mayo Clinic Methodist Campus | Rochester | Minnesota | 55905 | Recruiting |
| Mount Sinai | New York | New York | 10128 | Recruiting |
| The Cleveland Clinic Foundation | Cleveland | Ohio | 44195 | Recruiting |
| WellSpan Health | York | Pennsylvania | 17403 | Recruiting |
| Riverside Health | Newport News | Virginia | 23606 | Recruiting |
| CAMC Institute for Academic Medicine - Cancer Research Center | Charleston | West Virginia | 25304 | Recruiting |
| WVU Cancer Institute | Morgantown | West Virginia | 26506 | Not yet recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05804370, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 13, 2026 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05804370 live on ClinicalTrials.gov.